Insilico Medicine launches industry-first longevity board to accelerate AI-driven aging research for drug discovery

CAMBRIDGE, MA, April 21, 2026 — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the strategic establishment of the industry’s first Longevity Board (Board). The initiative will provide scientific oversight and strategic guidance for AI-powered aging research and drug discovery, accelerating the development of treatments that target the fundamental biological processes of aging, and advancing the transition from reactive disease treatment to proactive health span and peak span extension. The Board will oversee work-in-life models, biomarkers of aging, identification of dual-purpose targets related to aging, longevity, and disease, and clinical development that uses biomarkers and basic models to test the effects of therapeutics on the hallmarks of aging.

Bridging major pharmaceutical companies and longevity science

The initial committee consists of prominent scientists involved in aging and disease research, including:

• Longevity Chairman: Dr. Andrew Adams, Group Vice President, Molecular Discovery, Eli Lilly and Company
• Dr. Michael Levitt, 2013 Nobel Prize Laureate in Chemistry, In Silico SAB Member since 2014
• Dr. Denica Milanova, Founder and CEO of Medici Therapeutics, Insilico Board of Directors
• Alex Zhavoronkov, PhD, Insilico Medicine Co-CEO, Insilico Board of Directors
• Dr. Feng Ren, Insilico Medicine Co-CEO, Insilico Board of Directors
• CY Leung, PhD, Healthcare Partners, Value Partners, Insilico Board of Directors

Andrew Adams, vice president of Lilly’s Molecular Discovery Group, leads the board as chairman. Dr. Adams’ appointment bridges a critical gap between cutting-edge longevity science and large-scale drug development.

Dr. Adams gained industry attention at the 11th and 12th Annual Aging Research and Drug Discovery (ARDD) as a visionary in pharmaceutical modality innovation. In his keynote speech, “GLP-1s: The world’s first longevity drug?”clarifies the emerging role of metabolic regulators in longevity and aligns seamlessly with in silico’s vision of extending healthy and productive lives through dual-purpose therapies.

As Chairman, Dr. Adams’ deep expertise in genetic drug design and large-scale R&D operations will provide Insilico with the “Big Pharma” perspective needed to transition experimental longevity compounds into commercially viable medicines. By integrating his strategic insights into Insilico’s generative AI platform, the Board aims to accelerate the transition of experimental longevity compounds into commercially viable and effective medicines that can be integrated into mainstream healthcare systems.

A new wave of longevity research

Although longevity research has recently become a global trend, this field is not new. Already in the 1990s, early pioneers sought to directly target aging, investigating approaches such as telomerase activation, stem cell biology, and others alongside other promising hypotheses.

A new generation of longevity biotech companies is now emerging with more pragmatic, clinically-based strategies. Rather than pursuing “anti-aging” treatments head-on, they focus on diseases closely associated with aging, such as obesity, muscle atrophy, metabolic disorders, fibrosis, anemia, and cancer. The strategy is to first develop drugs for these indications and then expand their potential applications to a broader range of aging-related interventions.

Insilico Medicine is at the forefront of this new wave. Insilico leverages generative AI to identify dual-purpose targets at the critical intersection of chronic disease and biological aging. This approach not only addresses pressing clinical needs, but also enables the company to develop therapies that modulate the fundamental biological processes of aging and effectively bridge the gap between treating disease and extending healthy lifespans.

10 years of commitment to longevity science

“Longevity science has matured greatly since Alex and I started working together more than a decade ago. What excites me most about this board is the combination of rigorous biological insight with the kind of large-scale computational power that can really move the needle.”Dr. Michael Levitt, winner of the 2013 Nobel Prize in Chemistry, said: “Aging is not a single problem. Aging is a deeply interconnected set of molecular and cellular processes, and only by systematically targeting its complexity, using AI tools sophisticated enough to map it, will we have a real chance of extending not just lifespan, but healthspan. I am proud to be part of an ambitious effort that is serious, scientifically grounded, and of great importance.”

Longevity has been at the heart of Insilico’s mission since its founding. The company’s journey caught the attention of the industry at the 2015 NVIDIA GTC conference. There, Dr. Alex Zhavoronkov, founder and CEO of Insilico, challenged the technology industry with provocative questions: “Can NVIDIA cure aging?” . Insilico Medicine scientists have published more than 50 research papers related to aging and longevity research, aging biomarkers, and therapeutic targets and treatments related to aging, longevity, and disease.

About in silico medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, advance life sciences innovation, and extend healthy lives for people around the planet. The company was listed on the main board of the Hong Kong Stock Exchange on December 30, 2025 with stock code 03696.HK.

By integrating AI and automation technologies with deep in-house drug discovery capabilities, Insilico provides innovative pharmaceutical solutions for unmet needs such as fibrosis, oncology, immunology, pain, obesity and metabolic disorders. Additionally, Insilico will expand Pharma.AI’s reach across a variety of industries, including advanced materials, agriculture, nutritional products, and veterinary medicine. For more information, please visit www.insilico.com.